title: [Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia].
abstract: The effectiveness of domestic alpha 2-interferon preparation reaferon was studied in vivo and in vitro for eradication of pathological hemopoietic clone in chronic myeloid leukemia. Reaferon administration for 1-30 months produced cytogenetic remission in 7%, hematological remission in 21%, partial hematological remission in 36% of the patients. Reaferon is indicated in chronic myeloid leukemia without splenomegaly. In the disease progression reaferon is uneffective. Mechanism of reaferon therapeutic action comprises three components: a direct antiproliferative effect on hemopoietic precursor cells, activation of cellular immunity, an effect on stem cell microenvironment.
authors.forename: K M
authors.initials: KM
authors.lastname: Abdulkadyrov
authors.forename: S I
authors.initials: SI
authors.lastname: Moiseev
authors.forename: E G
authors.initials: EG
authors.lastname: Shcherbakova
authors.forename: V A
authors.initials: VA
authors.lastname: Balashova
authors.forename: T V
authors.initials: TV
authors.lastname: Glazanova
authors.forename: O A
authors.initials: OA
authors.lastname: Rukavitsyn
authors.forename: I S
authors.initials: IS
authors.lastname: Martynkevich
authors.forename: S V
authors.initials: SV
authors.lastname: Gritsaev
authors.forename: M N
authors.initials: MN
authors.lastname: Blinov
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001856:Bone Marrow Examination; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins; D012074:Remission Induction; D018709:Statistics, Nonparametric; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D006918:Hydroxyurea
vernacular_title: Opyt primeneniia reaferona (al'fa 2-interferona) dlia lecheniia bol'nykh khronicheskim mieloleĭkozom.